AbbVie.
pharmaceutical company
- Reports this week
- 20
- Active events
- 16
- Connections
- 485
What's happening
Active this week
-
MarketBeat's screener has identified a list of dividend stocks.Well supported15 reports1 development inside
-
AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.Some support4 reports1 development inside
-
A tariff plan caused market tanking on August 22, 2025, impacting publicly traded companies including Golden Entertainment and AbbVie.Some support3 reports1 development inside
-
Medicare eligibility rules affect AbbVie drug pricing, while the FDA regulates Creon's classification and approval for Medicare beneficiaries.Some support1 report1 development inside
-
AbbVie and Cerevel Therapeutics successfully launched a new drug for Parkinson's disease, pending government coverage negotiations.Some support3 reports
-
A fund holding diverse stocks, including Canadian dividend stocks, was mentioned as part of its strategy.Some support1 report
-
Johnson & Johnson, JPMorgan Chase, and AbbVie are dividend payers in the VYM fund.Some support1 report
-
AbbVie and Boehringer Ingelheim are engaging with financial advisory firms regarding potential deals and discussing M&A strategies in the competitive pharmaceutical market.Some support1 report
-
Pete Sessions sold shares of Apple Inc. and AbbVie, with the transactions disclosed via SEC filings.Some support1 report
-
Lost patent protection for Humira in the US on August 20, 2025.Well supported11 reports
-
Pharmaceutical companies are producing testosterone replacement therapies, which are being touted as anti-aging treatments, while the U.S. military tests service members' levels.Some support2 reports1 development inside
-
AbbVie and Cisco are noted as large-cap holdings in the market.Some support1 report
-
AbbVie, Abbott Laboratories, and Johnson & Johnson were recommended as dividend stocks for retirees, operating in the healthcare sector.Some support2 reports1 development inside
-
Multiple major pharmaceutical companies were identified as industry peers for growth during a capital markets day.Some support1 report1 development inside
-
AbbVie, AstraZeneca, and Bristol-Myers Squibb collaborated on the AISB Bind AI initiative.Some support2 reports
-
Iambic Therapeutics announced multiple new partnerships, including collaborations with Jazz Pharmaceuticals and AbbVie, and received backing from Qatar Investment Authority and Nvidia.Well supported4 reports
Earlier this month
-
Medicare pricing negotiations are impacting major pharmaceutical companies, including AbbVie, Eli Lilly, and Merck, who are seeking pricing exemptions.Some support2 reports3 developments inside
-
AbbVie announces support for a scholarship program across Canada, coinciding with Josh Berman's leadership role in Crohn's and Colitis Canada.Some support1 report
-
Biosimilar erosion is impacting market share, and AbbVie, Procter & Gamble, and Johnson & Johnson are noted as major consumer goods players.Some support2 reports
-
Julien Perrier previously held senior roles at both AbbVie and Sanofi.Some support1 report
-
Syndax Pharmaceuticals and AbbVie are competing in the healthcare and biopharma sector.Some support2 reports
-
Norges Bank purchased a new position in AbbVie stock, leading to a required institutional holdings disclosure filed with the SEC on July 2, 2026.Well supported5 reports
-
Millennium Management increased its stake in AbbVie and purchased shares of SpaceX stock on September 12, 2026.Some support3 reports
-
HSBC raised its price target to $315, and the FDA issued a complete response letter regarding trenibotE.Some support1 report
-
AbbVie and Novo Nordisk are high-profile pharmaceutical stocks serving over 45 million people worldwide, with Cor acting as a significant distribution partner.Some support1 report
-
Morgan Stanley reaffirmed an overweight rating on AbbVie, and Barclays raised its price objective on September 10, 2026.Some support1 report
-
AbbVie executives outlined growth plans at a conference hosted by Wells Fargo.Some support1 report
-
Millennium Management increased its stakes in AbbVie and Costco, and Israel Englander founded the firm.Some support2 reports
-
AbbVie, AstraZeneca, and GSK are major players in global drug development, facing challenges in the drug class and pursuing licensing deals with Chinese biotechs.Some support1 report2 developments inside
-
Pharmaceutical companies, including AbbVie and GSK, funded studies comparing drug spending, with Michael Johnson discussing Australia vs. New Zealand spending.Some support1 report
-
AbbVie and Johnson & Johnson are top exposures in the VYM ETF, which itself holds Microsoft.Some support5 reports
-
The FDA reviewed gene therapy applications and provided milestone payments for dosing involving Regenxbio and AbbVie.Some support1 report1 development inside
-
AbbVie is listed on the Nasdaq stock exchange, and MarketBeat is reporting on its stock performance.Some support1 report
-
Financial results and stock performance comparisons among AbbVie, Johnson & Johnson, Eli Lilly, and Merck.Some support2 reports1 development inside
-
Companies including AbbVie, Verizon, Philip Morris International, and Southern Company were selected for dividend income.Some support2 reports
-
Citigroup and Royal Bank of Canada raised price targets and ratings for a company, with MarketBeat aggregating the financial data.Some support4 reports
-
AbbVie submitted an application for the Skyrizi induction regimen to the European Medicines Agency.Some support1 report
-
Moderna, Merck, and AbbVie are seeking new revenue streams to offset losses caused by patent expirations.Some support2 reports
One to three months ago
-
AbbVie, Altria, and CVX are being utilized in a dividend ladder investment strategy.Some support1 report
-
AbbVie submitted an application for risankizumab approval to the European Medicines Agency.Some support1 report
-
Ken Griffin increased his stake in AbbVie, a dividend king company.Some support5 reports
-
Bank of America and Norges Bank increased their holdings in AbbVie stock on August 16, 2026.Some support3 reports
-
AbbVie previously failed challenges against Vertex Pharmaceuticals in the context of Cystic Fibrosis (CF).Some support1 report
-
Citigroup, Bank of America, and BNP Paribas issued rating updates and price targets for AbbVie stock on August 13, 2026.Some support2 reports
-
AbbVie reached a definitive agreement valued at $10.9 billion with Apogee Therapeutics.Well supported6 reports1 development inside
-
AbbVie is facing operational challenges stemming from siloed enterprise data systems.Some support1 report
-
State law in South Dakota limiting pharmaceutical market freedom was upheld by Judge Roberto Lange's court opinion.Some support1 report
-
Sionna licensed prospects from AbbVie on August 10, 2026.Some support1 report
-
Cencora is identified as a wholesale distributor for AbbVie, while both AbbVie and Abbott Laboratories are noted as healthcare industry leaders.Some support4 reports
-
AbbVie, Eli Lilly, UnitedHealth Group, and Johnson & Johnson are major holdings in the XLV ETF and dominate the healthcare sector basket.Some support2 reports
-
Amie Phinney was hired as Strategy & Business Advisor by Defence Therapeutics.Some support2 reports
-
Potential merger discussions involving major pharmaceutical companies like Eli Lilly, AstraZeneca, and AbbVie are underway.Some support2 reports
-
The acquisition of Apogee Therapeutics by AbbVie is expected to close in Q3.Some support1 report
-
AbbVie, Incyte, and Biogen are noted as peers in the biotechnology segment after reporting their Q2 financial results.Some support2 reports
-
AbbVie is utilizing basket trials for its oncology development efforts.Some support1 report
-
Both AbbVie and Apple Inc. are held by the DGRO fund.Some support1 report
-
AbbVie and Genmab will engage global regulatory authorities regarding their joint development efforts.Well supported8 reports1 development inside
-
Galderma, headquartered in Zug, competes with AbbVie's Botox injectables.Some support1 report
-
AbbVie, Bristol-Myers Squibb, Eli Lilly, and AstraZeneca participated in drug delivery innovation discussions and partnerships.Some support1 report1 development inside
-
Major pharmaceutical companies, including Eli Lilly, Johnson & Johnson, and AbbVie, are significant holdings in various health care ETFs.Some support5 reports2 developments inside
No events began in the chosen period. Widen it, or reset.
Around AbbVie this week
News at the entities that move AbbVie most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves AbbVie
-
Health Canada StructuralCanadian Blood Services faces union calls for contract termination after Health Canada issued a non-compliance rating.Moves AbbVie
-
Medicare StructuralLeaders call for slowing AI development pace, concurrent with an AI model built by OpenAI being hacked via the Medicare portal.Moves AbbVie
-
Eli Lilly and Company OperationalExxonMobil, Berkshire Hathaway, and Eli Lilly are top holdings in the Avantis ETF.Moves AbbVie
-
European Commission StructuralA European Commission summit focused on strategic cooperation, minerals, and pivoting away from the United States toward the EU.Moves AbbVie
-
Norges Bank TransactionalNorges Bank bought a new position in Qualcomm shares, coinciding with buy ratings and price targets from TD Cowen, reported by MarketBeat.Moves AbbVie
Connections
The 40 strongest of 485, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Cerevel Therapeutics Structural
AbbVie successfully acquired Cerevel Therapeutics for $8.7 billion, integrating its technology into the larger entity.
-
FDA Structural
The FDA formally evaluates, approves, and manages the market access for AbbVie's pharmaceutical products.
-
Genmab Operational
AbbVie and Genmab are actively engaged in joint development, clinical trials, and commercialization planning for cancer therapies, including profit-sharing agreements.
-
Securities and Exchange Commission Structural
AbbVie is subject to mandatory regulatory filings and disclosure requirements enforced by the Securities and Exchange Commission.
-
AstraZeneca Operational
AbbVie and AstraZeneca are direct competitors in oncology and dyslipidemia, while also engaging in strategic collaborations, such as AI initiatives.
-
Halozyme Therapeutics Structural
AbbVie utilizes proprietary ENHANZE technology licensed from Halozyme Therapeutics.
-
Research Triangle Transactional
AbbVie plans a $1.4B investment in the Research Triangle region.
-
Health Canada Structural
Health Canada formally regulates and approves products and operations of AbbVie.
Show all 40 connections
-
Bristol-Myers Squibb Operational
The companies are active pharmaceutical peers engaged in market competition and collaborative research initiatives.
-
Cantor Fitzgerald Operational
Cantor Fitzgerald provides financial ratings, price targets, and market commentary on AbbVie shares.
-
Johnson & Johnson Operational
AbbVie and Johnson & Johnson are direct competitors in the biopharmaceutical sector, vying for market share in oncology and immunology.
-
Cencora Structural
AbbVie utilizes Cencora as a wholesale partner to distribute a concentrated portion of its U.S. sales market.
-
Medicare Structural
AbbVie's market access, pricing, and launch success are structurally dependent on Medicare's coverage and negotiation decisions.
-
Eli Lilly and Company Operational
AbbVie and Eli Lilly are direct competitors in the global pharmaceutical market, vying for market share and therapeutic dominance.
-
HUMIRA Structural
AbbVie manages HUMIRA as a legacy asset, navigating its lifecycle, patent loss, and biosimilar competition while transitioning its portfolio.
-
European Commission Structural
The European Commission formally evaluates and grants market authorization for AbbVie's pharmaceutical products in the European market.
-
SEC Structural
AbbVie must comply with SEC regulations regarding institutional investment activity and stock holdings disclosure.
-
Norges Bank Transactional
Norges Bank has repeatedly invested in and acquired stakes in AbbVie shares.
-
Royalty Pharma Structural
Royalty Pharma holds ongoing royalty rights to AbbVie's products, generating revenue from AbbVie's sales.
-
Galderma Operational
The two companies are direct competitors in the market for injectables, specifically pitting Galderma's products against AbbVie's Botox.
-
Enanta Pharmaceuticals (United States) Structural
AbbVie commercializes products developed by Enanta, providing Enanta with royalty revenue and funding its operations.
-
Pfizer Operational
AbbVie and Pfizer are direct, high-stakes competitors operating in the oncology and broader pharmaceutical markets.
-
Citadel Transactional
Citadel has significantly increased its financial stake in AbbVie shares through share purchases.
-
Gilgamesh Pharmaceuticals Transactional
AbbVie has repeatedly acquired drug programs and candidates from Gilgamesh Pharmaceuticals.
-
Sanofi Operational
The companies are actively competing in the pharmaceutical market, evidenced by direct product rivalry and shared M&A pursuit.
-
ReGenX Biosciences (United States) Operational
AbbVie and ReGenX Biosciences maintain an ongoing operational partnership focused on joint drug development and clinical trials.
-
Food and Drug Administration Structural
AbbVie relies on the FDA for regulatory review, designation, and market approval of its products.
-
Biogen Operational
AbbVie and Biogen are identified as direct competitors and peers operating in the biotechnology and neuroscience markets.
-
Sarah Cannon Research Institute Operational
AbbVie and Sarah Cannon Research Institute are engaged in strategic alliances and clinical trials for cancer therapy innovations.
-
Morgan Stanley Mentioned together
Morgan Stanley provides financial ratings and price targets based on analysis of AbbVie's stock and growth prospects.
-
Guggenheim Partners Transactional
AbbVie engages with Guggenheim Partners in a transactional capacity regarding corporate deals and financial matters.
-
Ken Griffin Transactional
Ken Griffin's fund has repeatedly increased its investment stake in AbbVie.
-
Durham County Transactional
Durham County is considering offering a $15M incentive package to secure AbbVie investment.
-
Bank of America Mentioned together
Bank of America provides investment ratings and price targets for AbbVie stock.
-
Columbia University Operational
The company is engaged in an active, ongoing collaboration with the university to develop an AI model, leveraging both industry application and academic research.
-
European Medicines Agency Structural
The EMA reviews and grants/denies market approval for AbbVie's pharmaceutical products in Europe.
-
Donald Trump Operational
Donald Trump's policy threats and executive orders actively influence AbbVie's drug pricing and domestic investment strategies.
-
CytomX Therapeutics (United States) Operational
AbbVie and CytomX Therapeutics are engaged in a formal partnership for collaborative drug discovery and revenue sharing.
-
Vanguard Structural
Vanguard's funds, such as VYM, hold shares of AbbVie, establishing an ownership relationship.
-
Wells Fargo Operational
Wells Fargo provides financial ratings and market coverage for AbbVie, which utilizes their platform for corporate announcements.
History
Events by the month they beganSeptember 2026
24 events- AbbVie and Cerevel Therapeutics successfully launched a new drug for Parkinson's disease, pending government coverage negotiations.
- A fund holding diverse stocks, including Canadian dividend stocks, was mentioned as part of its strategy.
- Johnson & Johnson, JPMorgan Chase, and AbbVie are dividend payers in the VYM fund.
- AbbVie and Boehringer Ingelheim are engaging with financial advisory firms regarding potential deals and discussing M&A strategies in the competitive pharmaceutical market.
- Pete Sessions sold shares of Apple Inc. and AbbVie, with the transactions disclosed via SEC filings.
- AbbVie and Cisco are noted as large-cap holdings in the market.
- Multiple major pharmaceutical companies were identified as industry peers for growth during a capital markets day.
- AbbVie, AstraZeneca, and Bristol-Myers Squibb collaborated on the AISB Bind AI initiative.
- Iambic Therapeutics announced multiple new partnerships, including collaborations with Jazz Pharmaceuticals and AbbVie, and received backing from Qatar Investment Authority and Nvidia.
- AbbVie announces support for a scholarship program across Canada, coinciding with Josh Berman's leadership role in Crohn's and Colitis Canada.
- Biosimilar erosion is impacting market share, and AbbVie, Procter & Gamble, and Johnson & Johnson are noted as major consumer goods players.
- Julien Perrier previously held senior roles at both AbbVie and Sanofi.
- Syndax Pharmaceuticals and AbbVie are competing in the healthcare and biopharma sector.
- Millennium Management increased its stake in AbbVie and purchased shares of SpaceX stock on September 12, 2026.
- HSBC raised its price target to $315, and the FDA issued a complete response letter regarding trenibotE.
- AbbVie and Novo Nordisk are high-profile pharmaceutical stocks serving over 45 million people worldwide, with Cor acting as a significant distribution partner.
- Morgan Stanley reaffirmed an overweight rating on AbbVie, and Barclays raised its price objective on September 10, 2026.
- AbbVie executives outlined growth plans at a conference hosted by Wells Fargo.
- Millennium Management increased its stakes in AbbVie and Costco, and Israel Englander founded the firm.
- AbbVie, AstraZeneca, and GSK are major players in global drug development, facing challenges in the drug class and pursuing licensing deals with Chinese biotechs.
- Pharmaceutical companies, including AbbVie and GSK, funded studies comparing drug spending, with Michael Johnson discussing Australia vs. New Zealand spending.
- AbbVie and Johnson & Johnson are top exposures in the VYM ETF, which itself holds Microsoft.
- AbbVie is listed on the Nasdaq stock exchange, and MarketBeat is reporting on its stock performance.
- Companies including AbbVie, Verizon, Philip Morris International, and Southern Company were selected for dividend income.
August 2026
17 events- Medicare eligibility rules affect AbbVie drug pricing, while the FDA regulates Creon's classification and approval for Medicare beneficiaries.
- The FDA reviewed gene therapy applications and provided milestone payments for dosing involving Regenxbio and AbbVie.
- Financial results and stock performance comparisons among AbbVie, Johnson & Johnson, Eli Lilly, and Merck.
- Citigroup and Royal Bank of Canada raised price targets and ratings for a company, with MarketBeat aggregating the financial data.
- AbbVie submitted an application for the Skyrizi induction regimen to the European Medicines Agency.
- Moderna, Merck, and AbbVie are seeking new revenue streams to offset losses caused by patent expirations.
- AbbVie, Altria, and CVX are being utilized in a dividend ladder investment strategy.
- AbbVie submitted an application for risankizumab approval to the European Medicines Agency.
- Ken Griffin increased his stake in AbbVie, a dividend king company.
- Bank of America and Norges Bank increased their holdings in AbbVie stock on August 16, 2026.
- AbbVie previously failed challenges against Vertex Pharmaceuticals in the context of Cystic Fibrosis (CF).
- Citigroup, Bank of America, and BNP Paribas issued rating updates and price targets for AbbVie stock on August 13, 2026.
- AbbVie is facing operational challenges stemming from siloed enterprise data systems.
- State law in South Dakota limiting pharmaceutical market freedom was upheld by Judge Roberto Lange's court opinion.
- Sionna licensed prospects from AbbVie on August 10, 2026.
- Cencora is identified as a wholesale distributor for AbbVie, while both AbbVie and Abbott Laboratories are noted as healthcare industry leaders.
- Potential merger discussions involving major pharmaceutical companies like Eli Lilly, AstraZeneca, and AbbVie are underway.
July 2026
7 events- Pharmaceutical companies are producing testosterone replacement therapies, which are being touted as anti-aging treatments, while the U.S. military tests service members' levels.
- Norges Bank purchased a new position in AbbVie stock, leading to a required institutional holdings disclosure filed with the SEC on July 2, 2026.
- The acquisition of Apogee Therapeutics by AbbVie is expected to close in Q3.
- AbbVie, Incyte, and Biogen are noted as peers in the biotechnology segment after reporting their Q2 financial results.
- AbbVie is utilizing basket trials for its oncology development efforts.
- Both AbbVie and Apple Inc. are held by the DGRO fund.
- Galderma, headquartered in Zug, competes with AbbVie's Botox injectables.
Show 1 earlier month
June 2026
12 events- MarketBeat's screener has identified a list of dividend stocks.
- AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.
- A tariff plan caused market tanking on August 22, 2025, impacting publicly traded companies including Golden Entertainment and AbbVie.
- Lost patent protection for Humira in the US on August 20, 2025.
- AbbVie, Abbott Laboratories, and Johnson & Johnson were recommended as dividend stocks for retirees, operating in the healthcare sector.
- Medicare pricing negotiations are impacting major pharmaceutical companies, including AbbVie, Eli Lilly, and Merck, who are seeking pricing exemptions.
- AbbVie reached a definitive agreement valued at $10.9 billion with Apogee Therapeutics.
- AbbVie, Eli Lilly, UnitedHealth Group, and Johnson & Johnson are major holdings in the XLV ETF and dominate the healthcare sector basket.
- Amie Phinney was hired as Strategy & Business Advisor by Defence Therapeutics.
- AbbVie and Genmab will engage global regulatory authorities regarding their joint development efforts.
- AbbVie, Bristol-Myers Squibb, Eli Lilly, and AstraZeneca participated in drug delivery innovation discussions and partnerships.
- Major pharmaceutical companies, including Eli Lilly, Johnson & Johnson, and AbbVie, are significant holdings in various health care ETFs.